Shares of Applied Digital, WeRide, and Recursion Pharmaceuticals experienced declines in after-hours trading Tuesday following Nvidia’s latest 13F filing, revealing the semiconductor giant has reduced its stakes in these companies. This move signals a recalibration of Nvidia’s investment portfolio, impacting investor sentiment, particularly within the rapidly evolving artificial intelligence landscape. The news comes as investors closely watch the movements of major players in the tech sector, seeking to understand shifts in strategy and potential implications for future growth. Understanding these changes in Nvidia’s holdings is crucial for investors tracking the performance of these companies and the broader AI market.
Nvidia’s decision to trim its holdings in these companies—a data center operator, a Chinese self-driving firm, and an AI-driven drug developer—occurred during the final three months of 2025, according to the filing. While the divestment may raise concerns, analysts suggest the changes are part of a broader portfolio adjustment rather than a negative assessment of the companies’ long-term prospects. The semiconductor giant had previously invested $50 million in approximately 7.7 million shares of Recursion Pharmaceuticals as of June 30, 2025, according to The Globe and Mail.
Recursion Pharmaceuticals Sees Dip After Nvidia Stake Reduction
Recursion Pharmaceuticals (NASDAQ: RXRX), a clinical-stage biotech company leveraging artificial intelligence in drug discovery, saw its stock price close at $3.38, down 0.57% on Wednesday, February 18, 2026, according to Sherwood News. The company combines automated experimentation with machine learning to accelerate the identification of potential drug candidates. Nvidia’s reduced stake in Recursion comes at a time when the biotech industry is increasingly turning to AI to streamline the drug development process and reduce costs.
The leverage of AI in drug discovery is gaining traction as it allows researchers to analyze vast amounts of data and identify potential drug candidates more efficiently than traditional methods. Recursion Pharmaceuticals is at the forefront of this trend, utilizing its technology platform to accelerate the development of new therapies. However, the company, like others in the biotech sector, faces significant risks and uncertainties, including the challenges of clinical trials and regulatory approvals.
Applied Digital and WeRide Also Affected
Applied Digital (NASDAQ: APLD), a data center operator, also experienced a decline following Nvidia’s reduced position. Nvidia was previously the seventh-largest holder of Applied Digital as of the end of the third quarter of 2025. While Nvidia has reduced its direct stake, it still maintains some exposure to Applied Digital through its substantial position in CoreWeave, which acquired warrants in APLD last June. The demand for data center capacity is growing rapidly, driven by the increasing adoption of cloud computing and AI applications.
WeRide, a Chinese self-driving firm, also saw its stock dip after Nvidia exited its position. The self-driving car industry is highly competitive, with numerous companies vying for market share. WeRide is one of the leading players in China, but faces challenges in navigating the regulatory landscape and scaling its technology. The future of self-driving cars remains uncertain, but the potential benefits are significant, including increased safety and efficiency.
Nvidia’s Broader Portfolio Adjustments
Nvidia also sold its holdings of Arm Holdings, but this was partially offset by positive developments related to its expanded partnership with Meta. Arm-based CPUs are expected to play a more prominent role in data center environments, potentially boosting Nvidia’s volumes and selling prices. Nvidia added positions in Nokia, Intel, and Synopsys in the fourth quarter of 2025, all of which had been previously announced. Its Coreweave and Nebius positions remained unchanged relative to the third quarter.
These portfolio adjustments suggest that Nvidia is strategically reallocating its investments to focus on areas with the greatest potential for growth and profitability. The company’s moves reflect the dynamic nature of the tech industry and the need for companies to adapt to changing market conditions. Nvidia’s decisions are closely watched by investors, as they can provide insights into the company’s outlook and priorities.
The semiconductor industry is currently experiencing a period of rapid innovation and growth, driven by the increasing demand for chips in a wide range of applications, including smartphones, computers, and automobiles. Nvidia is a leading player in this industry, and its investments are shaping the future of technology.
Investors will be closely monitoring Nvidia’s next 13F filing, which will provide further insights into the company’s investment strategy and portfolio adjustments. The filing is expected to be released in the coming months and will offer a snapshot of Nvidia’s holdings as of March 31, 2026. This information will be crucial for investors seeking to understand the company’s long-term vision and potential for future growth.
Disclaimer: I am a board-certified physician and medical writer. This article provides information for general knowledge and informational purposes only, and does not constitute medical or investment advice. We see essential to consult with a qualified healthcare professional or financial advisor for any health concerns or before making any decisions related to your health or investments.
Share your thoughts on Nvidia’s investment moves and their potential impact on the tech industry in the comments below.
Keep reading
